RESEARCH PAPER
Comparative analysis of the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS treated with isoniazid
1
National Medical University, Kazakhstan
2
KIT Royal Tropical Institute, The Netherlands
3
University of Economics and Innovation, Lublin, Poland
4
Institute of Rural Health, Lublin, Poland
Corresponding author
Ann Agric Environ Med. 2019;26(3):462-467
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The epidemic of human immunodeficiency virus has had a tremendous effect on the epidemic of tuberculosis. Together with the spread of HIV, a great increase has been observed in morbidity due to tuberculosis, both in endemic countries and in those where earlier, as a result of treatment, the frequency of occurrence of tuberculosis had decreased. In 2018, the WHO data demonstrated that the EECA region was the only region worldwide where the epidemics of HIV was still rapidly increasing. The EECA region still struggles with a serious epidemic of tuberculosis.
Material and methods:
Materials and method. The research method applied was comparative analysis of the results of own study and studies by other researchers, concerning the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS when treated with isoniazid.
Results:
Results. In own study, it was found that primary morbidity among patients administered isoniazid significantly decreased within 5 years. Incidence rates of primary morbidity were significantly lower than among patients who had not received isoniazid. Relevant studies conducted worldwide, in many cases differed from own study with respect to both the results and approach to the problem, by country or selection of the type of patients participating in the study. However, in all studies, isoniazid was generally a safe and well-tolerated drug, without special side-effects.
Conclusions:
Conclusions. All studies analyzed concerning the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS treated with isoniazid, confirmed the effectiveness of this drug. In the compared studies, applied isoniazid preventive therapy showed no difference in effectiveness according to its duration. Analyzed studies showed similar effectiveness also with respect to a decrease in mortality among patients with TB/HIV/AIDS
The epidemic of human immunodeficiency virus has had a tremendous effect on the epidemic of tuberculosis. Together with the spread of HIV, a great increase has been observed in morbidity due to tuberculosis, both in endemic countries and in those where earlier, as a result of treatment, the frequency of occurrence of tuberculosis had decreased. In 2018, the WHO data demonstrated that the EECA region was the only region worldwide where the epidemics of HIV was still rapidly increasing. The EECA region still struggles with a serious epidemic of tuberculosis.
Material and methods:
Materials and method. The research method applied was comparative analysis of the results of own study and studies by other researchers, concerning the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS when treated with isoniazid.
Results:
Results. In own study, it was found that primary morbidity among patients administered isoniazid significantly decreased within 5 years. Incidence rates of primary morbidity were significantly lower than among patients who had not received isoniazid. Relevant studies conducted worldwide, in many cases differed from own study with respect to both the results and approach to the problem, by country or selection of the type of patients participating in the study. However, in all studies, isoniazid was generally a safe and well-tolerated drug, without special side-effects.
Conclusions:
Conclusions. All studies analyzed concerning the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS treated with isoniazid, confirmed the effectiveness of this drug. In the compared studies, applied isoniazid preventive therapy showed no difference in effectiveness according to its duration. Analyzed studies showed similar effectiveness also with respect to a decrease in mortality among patients with TB/HIV/AIDS
REFERENCES (38)
1.
Global AIDS Update: Miles to go: closing gaps, breaking barriers, righting injustices. UNAIDS Joint United Nations Programme on HIV/AIDS 2018 http://www.unaids.org/sites/de... (access: 2019.04.03).
2.
UNAIDS data 2018. Joint United Nations Programme on HIV/AIDS 2018 http://www.unaids.org/sites/de... (access: 2019.04.03).
3.
Regional Overview 2.2 Eurasia. Global State of Harm Reduction 2016 https://www.hri.global/files/2... (access: 2019.04.03).
4.
Gokengin D, et al. HIV care in Central and Eastern Europe: How close are we to the target? Int J Infect Dis. 2018; 70: 121–130.
5.
Gopalan N, Chandrasekaran P, Swaminathan S, Tripathy S. Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res Ther. 2016; 26(13): 34.
6.
World Health Organisation. Systematic screening for active tuberculosis. Principle and recommendations. World Health Organisation. http://apps.who.int/iris/bitst.... (access:2018.12.08).
7.
WHO treatment guidelines for drug-resistant tuberculosis: 2016.http://apps.who.int/iris/bitst... (access:2019.01.20).
8.
World Health Organization. The shorter MDR-TB regimen. 2016. http://www.who.int/tb/Short_MD.... (access:2018.12.08).
9.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/conten.... (access:2018.12.08).
13.
Tuberculosis surveillance and monitoring in Europe 2018. Surveillance Report WHO Regional Office for Europe. https://ecdc.europa.eu/sites/p... (access: 2019.04.03).
14.
Tuberculosis Regional Eastern European and Central Asian Project (TB-REP). WHO Regional Office for Europe 2017. http://www.euro.who.int/__data... (access: 2019.04.03).
15.
UNAIDS. 2018 Global AIDS Update; July 2018. United Nations. Reinvigorating the AIDS response to catalyse sustainable development and United Nations reform: Report of the Secretary-General. June 2017. http://www.unaids.org/sites/de... (access: 2019.04.03).
16.
Swindells S, Ramchandani R, Gupta A, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019; 380(11).
17.
Vesga JF, Hallett TB, Reid MJA, et al. Assessing tuberculosis control priorities in high-burden settings: a modelling approach. Published online March 20, 2019, http://www.thelancet.com/lance... http://dx.doi.org/10.1016/S221... (access: 2019.04.03).
18.
Semu M, Fenta TG, Medhin G, Assefa D. Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study. BMC Infect Dis. 2017; 17: 5.
19.
Abossie A, Yohanes T. Assessment of isoniazid preventive therapy in the reduction of tuberculosis among ART patients in Arba Minch Hospital, Ethiopia. Ther Clin Risk Manag . 2017; 13: 361–366.
20.
Maharaj B, Gengiah TN, Yende-Zuma N, Gengiah S, Naidoo A, Naidoo K. Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART. Int J Tuberc Lung Dis. 2017; 21(5): 537–543.
21.
Zunza M, Gray DM, Young T, Cotton M, Zar HJ. Isoniazid for preventing tuberculosis in HIV-infected children. Cochrane Database Syst Rev. 2017; 8:CD006418. doi: 10.1002/14651858.CD006418.pub3.
22.
Charalambous S, Grant AD, Innes C, Hoffmann CJ, Dowdeswell R, Pienaar J, Fielding KL, Churchyard GJ. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS. 2010; 24 Suppl 5: S5–13.
23.
Podlekareva DN, Schultze A, Panteleev A, et al. One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid susceptibletuberculosis in Eastern Europe, Western Europe, and Latin America. AIDS. 2017; 31(3): 375–384.
24.
Nagu TJ, Aboud S, Mwiru R, Matee MI, Rao M, Fawzi WW, Zumla A, Maeurer MJ, Mugusi F. Tuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy. Int J Infect Dis. 2017; 56: 39–44.
25.
da Silva Escada RO, Velasque L, Ribeiro SR, Cardoso SW, Marins LMS, Grinsztejn E, da Silva Lourenço MC, Grinsztejn B, Veloso VG. Mortality in patients with HIV-1 and tuberculosis co-infection in Rio de Janeiro, Brazil associated factors and causes of death. BMC Infect Dis. 2017; 17(1): 373.
26.
Badje A, Moh R, Gabillard D, et al. Effect of isoniazid preventive therapy on risk of death in west African HIV-infected adults with high CD4 count: long-term follow up of the Temprano ANRS 12136 trial. Lancet Glob Health 2017; 5: e1080–89.
27.
Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Mosimaneotsile B, Motsamai OI, Shang N, Rose CE, Shepherd J. Tuberculosis incidence after 36 months’ isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. AIDS. 2015; 29(3): 351–9.
28.
Golub JE, Cohn S, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, Durovni B, Chaisson RE. Longterm protection from isoniazid preventive therapy for tuberculosis in HIV-infected patientsin a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis. 2015; 60(4): 639–45.
29.
Sumner T, Houben RM, Rangaka MX, Maartens G, Boulle A, Wilkinson RJ, White RG. Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. AIDS. 2016; 30(8): 1279–86.
30.
Samandari TM, Mosimaneotsile B, Agizew T, Nyirenda S, Tedla Z, Sibanda T, et al. Randomized, placebo-controlled trial of 6 vs 36 months isoniazid TB preventive therapy for HIV-infected adults in Botswana. In: Program and Abstracts of Conference on Retroviruses and Opportunistic Infections; 8–11 February 2009; Montreal, Canada.
31.
Martinson NB, Barnes G, Msandiwa R, Moulton L, Gray G, McIntyre J, et al. Novel regimens for treating latent TB in HIV infected adults in South Africa: a randomized clinical trial. In: Program and Abstracts of Conference on Retroviruses and Opportunistic Infections; 8–11 February 2009; Montreal, Canada.
32.
Swaminathan S, Menon PA, Perumal V, Santhanakrishnan R, Ramachandran R, Chinnaiah P, et al. Efficacy of a 6-month vs a 36-month regimen for prevention of TB in HIV-infected persons in India: a randomized clinical trial. In: Program and Abstracts of Conference on Retroviruses and Opportunistic Infections; 16–19 February 2010; San Francisco.
33.
Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 2007; 334:136.
34.
Grant AD, Fielding KL, Charalambous S, Chaisson RE, Churchyard GJ. Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality? AIDS 2010; 24 (suppl 5): S15–S18.
35.
Global HIV & AIDS statistics – 2018 fact sheet http://www.unaids.org/en/resou... (accessed 08.12.2018).
36.
Haileyesus Getahuna, Reuben Granichb, Delphine Sculiera, Christian Gunneberga, Leopold Blanca, Paul Nunna and Mario Raviglionea, Barriers and solutions, AIDS 2010; 24 (suppl 5): S57–S65.
37.
Briggs MA, Emerson C, Modi S, Taylor NK, Date A. Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature. J Acquir Immune Defic Syndr. 2015; 68.
38.
Ayele HT, Mourik MS, Debray TP, Bonten MJ. Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials. PLoS One. 2015; 10(11): e0142290.
Share
RELATED ARTICLE
| eISSN: | 1898-2263 |
| ISSN: | 1232-1966 |
Improvement of visual identification of the journal - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher Education allocated to the activities of disseminating science.
Generation of the DOI (Digital Object Identifier) - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher
© 2006-2024 Journal hosting platform by Bentus
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
